HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP) announces that the board of directors of the Company, on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due.
A restructuring plan is being put together by the Board, and the Company is actively pursuing financing. There is no assurance that the restructuring will be successful or that the Company will be able to secure a new source of financing.
About HAVN Life Sciences Inc
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.